Segment, Customer and Geographical Reporting (Tables)

3 Months Ended

Dec. 31, 2018

The Company’s segment information for the three months ended December 31, 2018 and 2017 is summarized below:

Results of Operations for the Three Months Ended December 31,

2018

	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	5,721,000		$	4,307,000		$	-		$	10,028,000
Gross profit		1,879,000			1,813,000			-			3,692,000
GM %		33	%		42	%		-			37	%
Operating expenses		1,885,000			1,879,000			53,000			3,817,000
Operating income (loss)		(6,000	)		(66,000	)		(53,000	)		(125,000	)

Depreciation and amortization		276,000			59,000			3,000			338,000
Capital expenditures		187,000			17,000			-			204,000

Intangibles, net		363,000			154,000			201,000			718,000
Goodwill		925,000			4,939,000			-			5,864,000
Total assets	$	21,870,000		$	8,109,000		$	205,000		$	30,184,000

Results of Operations for the Three Months Ended December 31,

2017

	Optics			Innovation and Development*			Biomedical			Total
Revenue	$	4,942,000		$	4,247,000		$	-		$	9,189,000
Gross profit		1,724,000			1,851,000			-			3,575,000
GM %		35	%		44	%		-			39	%
Operating expenses		1,576,000			1,723,000			445,000			3,744,000
Operating income (loss)		148,000			128,000			(445,000	)		(169,000	)

Depreciation and amortization		231,000			65,000			3,000			299,000
Capital expenditures		590,000			19,000			16,000			625,000

Intangibles, net		453,000			188,000			337,000			978,000
Goodwill		1,012,000			4,939,000			-			5,951,000
Total assets	$	18,969,000		$	8,114,000		$	614,000		$	27,697,000

*Formerly Contract Research

Revenue by geographic location in total and as a percentage of total revenue, for the three months ended December 31, 2018 and 2017 are as follows: